Prideapplication/xmlftp://ftp.pride.ebi.ac.uk/pride/data/archive/2026/08/PXD063398/Experimental_conditions.txtftp://ftp.pride.ebi.ac.uk/pride/data/archive/2026/08/PXD063398/AD_MS_049_OP1_D_S3-H4_1_6221.d.zipftp://ftp.pride.ebi.ac.uk/pride/data/archive/2026/08/PXD063398/AD_MS_049_PP1_A_S3-F12_1_6205.d.zipftp://ftp.pride.ebi.ac.uk/pride/data/archive/2026/08/PXD063398/AD_MS_049_OB-b1_A_S3-F11_1_6204.d.zipftp://ftp.pride.ebi.ac.uk/pride/data/archive/2026/08/PXD063398/AD_MS_049_OB-b1_D_S3-H2_1_6219.d.zipftp://ftp.pride.ebi.ac.uk/pride/data/archive/2026/08/PXD063398/AD_MS_049_OP1_C_S3-G11_1_6216.d.zipftp://ftp.pride.ebi.ac.uk/pride/data/archive/2026/08/PXD063398/AD_MS_049_PP1_D_S3-H3_1_6220.d.zipftp://ftp.pride.ebi.ac.uk/pride/data/archive/2026/08/PXD063398/AD_MS_049_PP1_B_S3-G5_1_6210.d.zipftp://ftp.pride.ebi.ac.uk/pride/data/archive/2026/08/PXD063398/AD_MS_049_OP1_B_S3-G6_1_6211.d.zipftp://ftp.pride.ebi.ac.uk/pride/data/archive/2026/08/PXD063398/AD_MS_049_OB-b1_B_S3-G4_1_6209.d.zipftp://ftp.pride.ebi.ac.uk/pride/data/archive/2026/08/PXD063398/AD_MS_049_OP1_A_S3-G1_1_6206.d.zipftp://ftp.pride.ebi.ac.uk/pride/data/archive/2026/08/PXD063398/AD_MS_049_DMSO_D_S3-G12_1_6217.d.zipftp://ftp.pride.ebi.ac.uk/pride/data/archive/2026/08/PXD063398/AD_MS_049_DMSO_A_S3-F9_1_6202.d.zipftp://ftp.pride.ebi.ac.uk/pride/data/archive/2026/08/PXD063398/Report.zipftp://ftp.pride.ebi.ac.uk/pride/data/archive/2026/08/PXD063398/AD_MS_049_OB-b1_C_S3-G9_1_6214.d.zipftp://ftp.pride.ebi.ac.uk/pride/data/archive/2026/08/PXD063398/AD_MS_049_PP1_C_S3-G10_1_6215.d.zipftp://ftp.pride.ebi.ac.uk/pride/data/archive/2026/08/PXD063398/AD_MS_049_OB-a1_B_S3-G3_1_6208.d.zipftp://ftp.pride.ebi.ac.uk/pride/data/archive/2026/08/PXD063398/AD_MS_049_OB-a1_A_S3-F10_1_6203.d.zipftp://ftp.pride.ebi.ac.uk/pride/data/archive/2026/08/PXD063398/AD_MS_049_DMSO_B_S3-G2_1_6207.d.zipftp://ftp.pride.ebi.ac.uk/pride/data/archive/2026/08/PXD063398/AD_MS_049_OB-a1_D_S3-H1_1_6218.d.zipftp://ftp.pride.ebi.ac.uk/pride/data/archive/2026/08/PXD063398/AD_MS_049_OB-a1_C_S3-G8_1_6213.d.zipftp://ftp.pride.ebi.ac.uk/pride/data/archive/2026/08/PXD063398/AD_MS_049_DMSO_C_S3-G7_1_6212.d.zipprimaryOK200a.barnard@imperial.ac.ukAmrita DateMass SpectrometryBottom-up proteomicsData-independent acquisitionΑ-helix mimeticsMdm2Whole proteomehttps://www.ebi.ac.uk/pride/archive/projects/PXD063398SJSA-1 cells were treated with helix mimetic MSM2 inhibitors in serum-free media for 1, 4, 10, or 24 h. Cells were lysed using 1% SDS and reduction and alkylaiton were carried out using TCEP (10 mM) and 2-chloroacetamide (40 mM). Protein precipitation was carried out using an sp4 protocol. A solution of trypsin (6.25 ng/μL) in 25 mM ammonium bicarbonate buffer was added to the protein pellet, and the pellet was digested overnight at 37 degrees celcius. Sample (10 ng) was loaded onto Evotips for processing using nanoLC-MS/MS using an Evosep One coupled with a timsTOF HT (Bruker) equipped with an 8 cm × 150 µm, 1.5 µm analytical column (Evosep).PridediaPASEF Bruker .d files were processed using library-free analysis in DIA-NN (version 1.8.1) 9 using the following parameters: Human database (downloaded from Uniprot on 6 June 2022 containing 79334 proteins); “deep learning-based spectra and RTs prediction” was enabled; trypsin with 1 missed cleavages; N-term Excision, C carbamidomethylation, Oxidation and N terminal Acetylation were enabled with maximum 2 variable modifications; MBR was enabled; quantification strategy set to “Robust LC (high precision)”; heuristic protein inference was disabled; Mass and MS1 accuracy set to 0.ProteomicsAnna BarnardPARTIALImperial College LondonHomo Sapiens (human)10.1039/D6CB00065Ga.date19@imperial.ac.ukImperial College LondonUnited KingdomfalseWhole proteome characterisation following treatment with α-helix mimetic inhibitors of MDM2A wide range of small molecule scaffolds capable of mimicking protein α-helices to modulate protein-protein interactions have been reported, yet their target selectivity is poorly understood. Here, we report the changes to the whole protoeme of SJSA-1 osteosarcoma cells following treatment with three structurally distinct classes of α-helix mimetics, N-substituted oligobenzamides, pyrrolopyrimidines, and oxopiperazines, all reported to inhibit the interaction between the tumour suppressor protein p53 and its negative regulator murine double minute 2 (MDM2).2026-08-052025-04-28PXD063398NEWT:6945NEWT:3555NEWT:2NEWT:157546NEWT:35554NEWT:38942NEWT:307972NEWT:32046NEWT:544496NEWT:2042546NEWT:45351NEWT:43179NEWT:4513NEWT:5722NEWT:376741NEWT:55153NCBITaxon:10407NEWT:1736309NEWT:309800NEWT:1211601NEWT:876138NEWT:237561NEWT:5833NEWT:6928NEWT:10036NEWT:36745NEWT:1351NEWT:1438992NEWT:2649997NEWT:272563NEWT:224326NCBITaxon:79857NEWT:1096976NEWT:95648NEWT:3885NEWT:3888NEWT:1589NEWT:135622NEWT:6915NEWT:3649NEWT:101510NEWT:3880NEWT:272559NEWT:3641NEWT:383379NEWT:466585NEWT:10029NEWT:1000589NEWT:85963NEWT:85962NEWT:317447NEWT:7955NEWT:7959NEWT:2261NEWT:31156NEWT:398580NEWT:4565NEWT:1264690NEWT:515619NEWT:192875NEWT:34305NEWT:59729NCBITaxon:183674NEWT:224308NEWT:84645NEWT:626528NEWT:139927NEWT:4558NEWT:209285NEWT:1283NEWT:931281NEWT:4550NEWT:1000561NEWT:197NCBITaxon:79824NEWT:4787NCBITaxon:4563NEWT:5755NEWT:44689NEWT:3218NEWT:5759NEWT:1736231NEWT:1270NEWT:2242NEWT:4784NEWT:11320NEWT:360106NEWT:286NEWT:287NEWT:10117NEWT:10239NEWT:10116NEWT:1280NEWT:1735272NEWT:83334NEWT:83332NEWT:44685NEWT:317513NEWT:1148NEWT:580240NEWT:294128NEWT:11676NEWT:55571NEWT:100226NEWT:4530NEWT:4896NEWT:75058NEWT:13616NEWT:1094343NEWT:296543NEWT:1773NEWT:1895NEWT:1182590NEWT:935293NEWT:64152NEWT:4924NEWT:749200NEWT:990346NEWT:145953NEWT:257309NEWT:100816NEWT:263NEWT:230741NEWT:52283NEWT:284812NCBITaxon:1313NEWT:43330NEWT:1603293NEWT:408169NEWT:44544NEWT:4911NEWT:645463NEWT:3702NEWT:129249NEWT:243277NEWT:990119NEWT:408172NEWT:408170NEWT:493760NEWT:260710NEWT:257313NEWT:400772NEWT:3708NEWT:128161NEWT:332648NEWT:106592NEWT:536231NEWT:460519NEWT:1187947NEWT:1432138NEWT:10312NEWT:1424507NCBITaxon:1773NEWT:9598NEWT:8030NEWT:1639NEWT:188229NEWT:3818NEWT:480NEWT:4909NEWT:67767NEWT:432359NEWT:46835NEWT:1182263NEWT:2711NEWT:376686NEWT:95486NEWT:9103NEWT:29159NEWT:253NEWT:10306NCBITaxon:2759NEWT:1233435NEWT:8022NEWT:145943NCBITaxon:4932NEWT:595536NEWT:240906NEWT:593117NEWT:3635NEWT:5811NEWT:235443NEWT:272624NEWT:411483NEWT:884019NEWT:198215NEWT:411490NEWT:983964NEWT:169963NEWT:32644NEWT:499175NEWT:109779NEWT:476272NEWT:3747NEWT:195051NEWT:367830NEWT:1255228NEWT:178616NEWT:410289NEWT:373153NEWT:352472NEWT:357NEWT:360094NEWT:470NEWT:1313NEWT:411469NEWT:84023NEWT:559292NEWT:39491NCBITaxon:5811NEWT:411464NEWT:411460NEWT:2014887NEWT:2762NEWT:1174673NEWT:562NEWT:411470NEWT:33952NEWT:2094720NCBITaxon:2697049NEWT:571256NEWT:28038NEWT:1663NEWT:1423NEWT:4932NEWT:3603NEWT:2759NEWT:3847NEWT:327159NEWT:178876NEWT:327160NEWT:573NEWT:9031NEWT:7091NEWT:241368NEWT:42528NEWT:190802NEWT:9778NEWT:150475NEWT:303NEWT:9417NEWT:7111NEWT:347515NEWT:1216979NEWT:5180NEWT:256737NEWT:115104NEWT:1121114NEWT:663NEWT:1081927NEWT:1238993NEWT:67825NEWT:185579NEWT:941442NEWT:220668NEWT:13076NEWT:1249668NEWT:317NEWT:7227NEWT:7469NEWT:885318NEWT:9402NEWT:415540NEWT:550NEWT:675060NEWT:4081NEWT:334542NEWT:554NEWT:98334NEWT:426428NEWT:7574NEWT:1715256NEWT:7215NEWT:575412NEWT:29204NEWT:2172103NEWT:507601NEWT:643680NCBITaxon:6157NEWT:746360NEWT:6239NEWT:470150NEWT:216257NEWT:102169NEWT:9986NEWT:4054NEWT:73239NEWT:226186NEWT:1268063NEWT:8782NEWT:1263854NEWT:435590NEWT:1902NEWT:160488NEWT:28104NEWT:1908NCBITaxon:2NEWT:985076NEWT:1215323NEWT:52641NEWT:7038NEWT:6192NEWT:28532NCBITaxon:38727NEWT:353152NEWT:2829NEWT:366581NEWT:216599NEWT:216595NEWT:243230NEWT:8355NEWT:9685NEWT:7029NEWT:1080772NEWT:1283300NEWT:6183NEWT:6063NEWT:334747NEWT:61235NEWT:6289NEWT:436486NEWT:6287NEWT:300641NEWT:727NEWT:9796NEWT:725NEWT:170187NEWT:260707NCBITaxon:6191NEWT:1836NEWT:185431NEWT:29760NEWT:260704NEWT:703612NEWT:260705NEWT:80863NEWT:2697049NEWT:105231NEWT:1216981NCBITaxon:6073NEWT:884204NEWT:6279NEWT:1123869NEWT:9544NEWT:7370NEWT:83906NEWT:607699NEWT:6282NEWT:208964NEWT:1134506NEWT:575584NEWT:38783NEWT:8727NEWT:4006NEWT:8726NEWT:6426NEWT:6669NEWT:10090NEWT:4120NEWT:51515NEWT:5693NEWT:8724NEWT:51511NEWT:92867NEWT:8723NEWT:5334NEWT:37334NEWT:382352NCBITaxon:10359NEWT:242619NEWT:632957NEWT:34073NEWT:373995NEWT:5689NEWT:544404NEWT:9925NEWT:8839NEWT:4232NEWT:2758385NEWT:4113NEWT:837NEWT:11298NEWT:171101NEWT:714NEWT:421932NEWT:196627NEWT:5691NEWT:48479NEWT:627025NEWT:1097677NEWT:61674NEWT:1117957NEWT:9913NEWT:4100NEWT:1076NEWT:6763NEWT:803NEWT:29722NEWT:380394NEWT:1692259NEWT:180066NEWT:135588NEWT:1843183NEWT:58002NEWT:326423NEWT:4577NEWT:1416333NEWT:5664NEWT:2157NEWT:1678078NEWT:749906NEWT:418985NEWT:146479NEWT:1911079NEWT:69373NEWT:264203NEWT:1480154NEWT:1274414NEWT:27606NEWT:59202NEWT:9975NEWT:9612NEWT:38865NEWT:51953NEWT:3197NEWT:9615NEWT:10299NEWT:860688NEWT:36329NEWT:1147787NCBITaxon:3044782NEWT:72407NEWT:349741NEWT:9605NEWT:9606NEWT:157295NEWT:641501NEWT:7668NEWT:915099NEWT:74940NEWT:9721NEWT:137221NEWT:1450511NEWT:1143193NEWT:411901NEWT:9838NEWT:105884NCBITaxon:9615NEWT:9839NEWT:58334NEWT:1193501NEWT:3055NEWT:58331NEWT:6326NEWT:6689NEWT:5476NEWT:299767NEWT:1274432NEWT:1274426NEWT:70448NEWT:9825NEWT:1274423NEWT:393765NEWT:698936NEWT:39946NEWT:9823NEWT:9940NEWT:521001NEWT:39947NEWT:1274420NEWT:5784580009-0008-4891-1643